Compare ANNX & MUC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANNX | MUC |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.7M | 1.0B |
| IPO Year | 2020 | 1997 |
| Metric | ANNX | MUC |
|---|---|---|
| Price | $5.32 | $10.61 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $16.50 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 252.1K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16,320.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.85 | $10.00 |
| 52 Week High | $7.18 | $11.04 |
| Indicator | ANNX | MUC |
|---|---|---|
| Relative Strength Index (RSI) | 44.52 | 43.32 |
| Support Level | $5.28 | $10.57 |
| Resistance Level | $5.61 | $10.90 |
| Average True Range (ATR) | 0.30 | 0.06 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 40.34 | 38.37 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
BlackRock MuniHoldings California Quality Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income taxes and California personal income taxes. The fund mainly invests in municipal obligations exempt from U.S. federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax) and California personal income taxes. Under normal market conditions, it invests a majority of its managed assets in investment-grade municipal obligations with remaining maturities of one year or more at the time of investment. It can also invest in below investment-grade securities, or directly in such securities or synthetically through the use of derivatives.